MII IG Kerndatensatz-Modul Molekulares Tumorboard
2027.0.0-ballot.1 - Germany

This page is part of the MII Implementation Guide Molecular Tumor Board (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions

Example Observation: 22.10.2023 CT T/A

English

Profile: MII PR MTB Response Befund version: 2027.0.0-ballot.1

partOf: Procedure Zytostatische Chemotherapie, Immuntherapie und antiretrovirale Therapie

status: Final

code: Status of regression of tumor (observable entity)

subject: Kim Musterperson (no stated gender), DoB: 1956-03-14

focus: Condition Bösartige Neubildung: Peritoneum, nicht näher bezeichnet

effective: 2023-10-22

value: Partial Response

method: RECIST

Components

-CodeValue[x]
*Presence of metastatic neoplasm in regional lymph node (observable entity)kein Lymphknotenbefall nachweisbar